Publications

Articles in scientific journals

The list below provides an overview of selected publications in English. The full list of publications linked to the TULUNG project is available in the Czech version of this website.

• Fiala O, Hošek P, Pešek M, Fínek J, Racek J, Büchler T, Poprach A, Hejduk K, Chloupková R, Sorejs O, Ecksteinová M, Vítovec M, Čížková K, Kučera R, Topolčan O. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma 2017; 64(4): 605-610.
• Fiala O, Pešek M, Skřičková J, Kolek V, Salajka F, Tomíšková M, Šatánková M, Kultan J, Kulíšková J, Svatoň M, Hrnčiarik M, Hejduk K, Chloupková R, Topolčan O, Hornychovč H, Novč M, Ryška A, Fínek J. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Tumor Biology 2017; 39(2): 1010428317691186.
• Fiala O, Pesek M, Finek J, Racek J, Minarik M, Benesova L, Bortlicek Z, Sorejs O, Kucera R, Topolcan O. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib. Neoplasma 2016; 63(3): 471-476.
• Fiala O, Pesek M, Finek J, Svaton M, Minarik M, Benesova L, Bortlicek Z, Kucera R., Topolcan O. Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. Anticancer Research 2016; 36(1): 447-453.
• Fiala O, Pesek M, Finek J, Svaton M, Sorejs O, Bortlicek Z, Kucera R, Topolcan O. Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy. Anticancer Research 2016; 36(1): 461-466.
• Fiala O, Pesek M, Finek J, Minarik M, Benesova L, Sorejs O, Svaton M, Bortlicek Z, Kucera R, Topolcan O. Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC. Anticancer Research 2016; 36(1): 455-460.
• Fiala O, Pesek M, Finek J, Topolčan O, Racek J, Svaton M, Kucera R, Minarik M, Benesova, L, Bortlicek Z, Chloupkova R, Poprach A, Buchler T. Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib. Anticancer Research 2016; 36(5): 2459-2465.
• Svaton M, Fiala O, Pesek M, Bortlicek Z, Minarik M, Benesova L, Topolcan O. The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. Anticancer Research 2016; 36(3): 1077-1082.
• Fiala O, Pešek M, Fínek J, Topolčan O, Racek J, Minárik M, Benešová L, Bortlíček Z, Poprach A, Büchler T. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. Tumor Biology 2015; 36(12): 9215–9222.
• Fiala O, Pešek M, Fínek J, Minárik M, Benešová L, Bortlíček Z, Topolčan O. Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation. Tumour Biology 2015; 36(8): 5801–5805.
• Fiala O, Pešek M, Fínek J, Krejčí J, Havel L, Hrnčiarik M, Salajka F, Bortlíček Z, Benešová L, Minárik M. Erlotinib in the treatment of advanced squamous cell NSCLC. Neoplasma 2013, 60(6): 676–682.
• Fiala O, Pešek M, Fínek J, Krejčí J, Říčař J, Bortlíček Z, Benešová L, Minárik M. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013; 60(1): 26–32.

Conference abstracts

• Skřičková, J, Hejduk, K, Bortlíček, Z, Pešek, M, Koubková, L. Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practice of Czech Republic. ERS Annual Congress, Wien, 1.-5. 9. 2012
• Skřičková, J, Bortlíček, Z, Hejduk, K, Pešek, M, Zatloukal, P, Kolek, V, Salajka, F, Koubková, L, Čoupková, H, Zemanová, M. The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts). 13th Central European Lung Cancer Conference, Praha, 24.-27. 6. 2012
• Skřičková, J, Bortlíček, Z, Hejduk, K, Pešek, M, Kolek, V, Koubková, L, Tomíšková, M, Roubec, J, Zatloukal, P, Salajka, F. Use of pemetrexed as first line treatment of advanced non-small cell lung cancer: The Czech Republic experience with the treatment of 237 patients (pts). 13th Central European Lung Cancer Conference, Praha, 24.-27. 6. 2012
• Kolek V, Pešek M, Grygárková I, Zatloukal P, Skřičková J, Sixtová D, Koubková L, Roubec J, Salajka F, Petruželka L, Vyzula R, Štícha M. A multicentre prospective study on pemetrexed in the second line chemotherapy of non small cell lung cancer. Data from routine clinical practice. 13th Central European Lung Cancer Conference, Praha, 24.-27. 6. 2012
• Čoupková, H, Skřičková, J, Hejduk, K, Bortlíček, Z, Kadlec, B, Salajka, F, Pešek, M, Kolek, V, Koubkova, L, Sixtova, D, Zatloukal, P, Roubec, J, Zemanová, M, Vyzula, R, Špelda, S. Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic. 2012 ASCO Annual Meeting, Chicago, 1.-5. 6. 2012

The TULUNG registry is a new project merging previous clinical registries Avastin, Tarceva, and Pemetrexed. A list of publications resulting from these projects is available below:

• Skřičková, J, Pešek, M, Zatloukal, P, Kolek, V, Salajka, F, Koubková, L, Krejčí, J, Tomíšková, M, Grygárková, Y, Havel L, Hrnčiarik, M, Skálová, B, Štícha, M. Klinický registr TARCEVA. Klinická onkologie 2010; 23(5): 361–363.
• Skrickova J, Pesek M, Zatloukal P, et al. Erlotinib in patients with advanced non-small-cell lung cancer: results on 973 patients from Tarceva register of Czech Republic. Journal of Thoracic Oncology 2010; 5(5): S88–S89.
• Skřičková, J, Pešek, M, Zatloukal, P, et al. Erlotinib u nemocných s nemalobuněčným karcinomem plic (NSCLC): účinný u všech podskupin nemocných i v Česke republice. XXXIV. Brněnské onkologické dny a XXII. Konference pro sestry a laboranty, Brno, 22.-24. 4. 2010.
• Babickova L, Tomiskova M, Skrickova J, et al. Analysis of treatment effects of erlotinib in non small cell lung cancer patients. EJC Supplements 2009; 7(2): 544–545.
• Skřičková, J, Tomíšková, M, Vašutová, I. Erlotinib v léčbě nemalobuněčného bronchogenního karcinomu. XXXIII. Brněnské onkologické dny a XXII. Konference pro sestry a laboranty, Brno, 16.–18. 4. 2009.
• Pesek, M, Krejci, J, Skrickova, J, et al. Erlotinib therapy in non small cell lung cancer patients - survival of patients on reduced erlotinib doses. Journal of Thoracic Oncology 2009; 4(9): S295–S296.
• Pesek, M, Krejci, J, Skrickova, J, et al. Erlotinib therapy in non small cell lung cancer patients-survival of "poor prognosis patients". Journal of Thoracic Oncology 2009; 4(9): S704.
• Skrickova J, Pesek M, Zatloukal P, et al. Erlotinib (Tarceva (R)) in patients with non-small-cell lung cancer (NSCLC): results on 394 patients from Tarceva Register of Czech Republic. Journal of Thoracic Oncology 2009; 4(9): S714–S714.
• Salajka F, Pesek M, Krejci J, et al. The influence of clinical predictors on the results of treatment with erlotinib in patients with advanced NSCLC. Journal of Thoracic Oncology 2009; 4(9): S799–S800.